Tag: SGLT-2 inhibitors

1. In this secondary analysis of the DECLARE-TIMI 58 trial, among 17,160 patients, dapagliflozin consistently reduced the risk of cardiovascular ...

This study summary is an excerpt from the book 2 Minute Medicine's The Classics in Medicine: Summaries of the Landmark ...

1. In patients with type 2 diabetes, sodium-glucose cotransporter 2 inhibitor (SGLT-2i) use was associated with reduced risk of composite ...

1. The use of sodium-glucose transport protein 2 inhibitors in patients with type 2 diabetes was associated with a lowered ...

1. Empaglifozin treatment was shown to have reduced rates of cardiovascular death or hospitalization in patients with heart failure and ...

1. Sotagliflozin was shown to lower the risk of total number of deaths from cardiovascular causes and hospitalizations and urgent ...

1. Sotagliflozin was shown to lower the risk of total number of deaths from cardiovascular causes and hospitalizations and urgent ...

1. The use of sodium-glucose cotransporter-2 (SGLT-2i) increased study participants’ risk of diabetic ketoacidosis (DKA) hospital presentations when compared to ...

1. No significant difference in severe UTIs was observed between patients starting SGLT-2 inhibitors for type 2 diabetes, compared to ...

1. No significant difference in severe UTIs was observed between patients starting SGLT-2 inhibitors for type 2 diabetes, compared to ...